Brennan Edward J. 4

What Happened Edward J. Brennan, Chief Scientific Officer of Medicus Pharma Ltd. (MDCX), was granted a derivative award on June 3, 2026: an option covering 25,000 shares reported at $0.00 per share (total reported value $0). This was a compensation award (transaction code A), not an open-market purchase or sale — no cash changed hands at grant and no shares were sold.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (appears timely).
• Security: Derivative (option) for 25,000 shares reported at $0.00 per share.
• Transaction type/code: Award/Grant (A).
• Vesting: The option was granted June 3, 2026 and vests quarterly in four equal installments over one year (see footnote).
• Shares owned after transaction: Not disclosed on this Form 4 (no immediate exercise occurred).
• No indication of a 10b5-1 plan, tax withholding sale, or late filing in the report.

Context This entry represents a standard equity-compensation grant to an executive rather than a market purchase or sale. As a derivative award, the option gives the holder the right to obtain shares in the future according to the vesting schedule; it does not increase current share count until vested and exercised. For retail investors, such grants are routine executive compensation and do not by themselves indicate immediate buying or selling pressure.